Preparation of 131I-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected rats

dc.contributor.authorInceboz T.
dc.contributor.authorYurt Lambrecht F.
dc.contributor.authorSurucu E.
dc.contributor.authorYilmaz O.
dc.contributor.authorYavasoglu A.
dc.contributor.authorDurkan K.
dc.contributor.authorBaykara B.
dc.contributor.authorBekis R.
dc.contributor.authorUner A.
dc.date.accessioned2019-10-27T08:24:01Z
dc.date.available2019-10-27T08:24:01Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractWe aimed to assess the ability of 131I-Pyrimethamine scintigraphy to detect the lesions of Toxoplasma gondii infection. An experimental model of toxoplasmosis was developed. The presence of toxoplasmosis was confirmed 60 days after implantation. Pyrimethamine was radioiodinated with I-131. The radioligand was validated by the requisite quality control tests to check its radiolabeling efficiency, in vitro stability and radiochemical purity etc. 131I-Pyrimethamine (specific activity: 7.08 MBq/mol) was injected intravenously into the tail vein of the control and infected rats. Static whole body images of the rats were acquired under the gamma camera at 5min, 45min, 2h, 6h, and 24h following the intravenous administration of the radioactivity (3.7 MBq/rat). Then the scintigraphic data were analyzed both visually and semiquantitatively. Regions of interest (ROIs) were drawn over the organs (thyroid, stomach, liver, bladder, and soft tissues) to calculate the ratios of the radiotracer in infected vs. control rats. The mean ratio of radiotracer in infected/control rats in the liver and diaphragm was over 1 at 45min which persisted till 24h. In conclusion, 131I-Pyrimethamine may be useful agent for diagnosis toxoplasmosis especially involving liver and diaphragm, needs further preclinical validation before being extended for use in clinical applications. © 2013 Informa UK, Ltd.en_US
dc.identifier.doi10.3109/1061186X.2012.736999en_US
dc.identifier.endpage179en_US
dc.identifier.issn1061-186X
dc.identifier.issue2en_US
dc.identifier.pmid23113799en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage175en_US
dc.identifier.urihttps://doi.org/10.3109/1061186X.2012.736999
dc.identifier.urihttps://hdl.handle.net/11454/26518
dc.identifier.volume21en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Drug Targetingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject131I-Pyrimethamineen_US
dc.subjectRadionuclide imagingen_US
dc.subjectToxoplasma gondiien_US
dc.subjectToxoplasmosisen_US
dc.subjectWistar raten_US
dc.titlePreparation of 131I-Pyrimethamine and evaluation for scintigraphy of experimentally Toxoplasma gondii-infected ratsen_US
dc.typeArticleen_US

Dosyalar